07:30 AM EDT, 09/12/2024 (MT Newswires) -- Fulcrum Therapeutics ( FULC ) shares dropped almost 70% premarket after the company said Thursday that its phase 3 REACH trial evaluating losmapimod in patients with facioscapulohumeral muscular dystrophy did not achieve its primary endpoint compared to placebo.

Moreover, secondary endpoints also did not achieve nominal statistical significance. As a result, the company plans to suspend future development of losmapimod.

Price: 2.99, Change: -5.86, Percent Change: -66.21